Table 2.
Risk of Adverse Cardiovascular Outcomes Among Breast Cancer Patients When Aromatase Inhibitor Switchers Are Compared With Those Continuing Tamoxifen, United Kingdom, 1998–2016
|
Outcome and Treatment Type |
No. of Events |
Person-Years of Follow-up |
Incidence | Risk Estimate | ||
|---|---|---|---|---|---|---|
| IR a | 95% CI | HR b | 95% CI | |||
| Myocardial infarction | ||||||
| Tamoxifen | 14 | 7,126 | 2.0 | 1.1, 3.3 | 1.00 | Referent |
| AIs | 18 | 3,820 | 4.7 | 2.8, 7.5 | 2.08 | 1.02, 4.27 |
| Ischemic stroke | ||||||
| Tamoxifen | 22 | 7,120 | 3.1 | 1.9, 4.7 | 1.00 | Referent |
| AIs | 19 | 3,831 | 5.0 | 3.0, 7.7 | 1.58 | 0.85, 2.93 |
| Heart failure | ||||||
| Tamoxifen | 14 | 7,128 | 2.0 | 1.1, 3.3 | 1.00 | Referent |
| AIs | 13 | 3,835 | 3.4 | 1.8, 5.8 | 1.69 | 0.79, 3.62 |
| Cardiovascular mortality | ||||||
| Tamoxifen | 36 | 7,134 | 5.0 | 3.5, 7.0 | 1.00 | Referent |
| AIs | 19 | 3,843 | 4.9 | 3.0, 7.7 | 0.87 | 0.49, 1.54 |
Abbreviations: AI, aromatase inhibitor; CI, confidence interval; HR, hazard ratio; IR, incidence rate.
a Number of cases per 1,000 person-years.
b HR obtained from the matched population.